ACE-031
Also known as: ACVR2B-Fc
ACE-031 (ramatercept) is a soluble fusion protein of the activin receptor IIB (ActRIIB) extracellular domain and human IgG1 Fc, developed by Acceleron Pharma as a myostatin/activin ligand trap for muscle-wasting disorders. Clinical development was HALTED in 2011 after unexpected vascular adverse events (epistaxis, telangiectasia) attributed to off-target BMP-9/10 inhibition. NOT FDA-approved; all further development was terminated. Now sold only as a grey-market research chemical. WADA-prohibited (myostatin inhibitor).
0 listings, ranked by trust score
Each row is a (vendor, peptide) pair. Click through for the listing detail, the vendor's full trust profile, and any COAs they've published.
No vendors carrying this peptide are indexed yet.
No COAs on file for ACE-031
No third-party tests indexed yet. Phase 2 will surface more vendor evidence as the dataset grows.